glp 1 receptor agonists and dpp 4 inhibitors glp-1 agonist inhibitor Role of DPP-4 in Clinical Practice GLP-1 DPP-4 fig2.gif

doi: 10.3748/wjg.v25.i18.2188 27 PaisPAlmeidaVYlmazMTeixeiraMC

Versus GLP-1 agonists GLP-1 agonists like semaglutide and tirzepatide have become popular for metabolic optimization and weight loss

Enhances the tablet's structural integrity

Regarding clinical intervention strategies, ferroptosis inhibitors and antioxidants provide promising new therapeutic options for CHD management

The largest trial involving DSIP to date, which included a total of 107 volunteers, reported that the peptide was generally well-tolerated with mostly minor side effects, which included [8]: Low blood pressure Increased sweating Headache Nausea Vertigo Considering that the drop in blood pressure was reported as moderate to severe in some patients, researchers should consider hypotension as a potentially exclusionary criterion for DSIP research